HPV vaccinations and cervical cancer in Japan: Flaws in alleged experimental evidence for molecular mimicry and animal models of HPV vaccine-induced "adverse reactions "

Abstract

In Japan, around 3,000 females have died of cervical cancer annually. Cervical cancer is caused by sexually transmitted infections of the human papillomavirus (HPV); it is preventable by vaccinations against oncogenic HPV types, such as types 16 and 18. In Japan, the proactive recommendations for HPV vaccinations were suspended in June 2013 due to public concerns about neuropsychological "diverse symptoms" following HPV vaccinations. The suspension resulted in the vaccination rate less than 1% among the eligible population. In April 2022, the Japanese government resumed the proactive HPV vaccination recommendations after 9 years of the suspension. Many Japanese people, however, still have concerns about the "diverse symptoms" as adverse reactions following HPV vaccinations. In this article, we critically evaluated the manuscripts cited in the HPV vaccine lawsuits in Japan, including computational and animal studies, which have been used as the theoretical basis for how HPV vaccinations could induce the "diverse symptoms." We concluded that all the manuscripts had scientific flaws, which should not be used to prove that HPV vaccinations could induce the adverse reactions. We wish that our current evaluation would contribute to eliminating baseless concerns about HPV vaccines, eventually increasing the rate of HPV vaccinations in Japan.